구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | HER2Bi-Armed Activated T Cells (HER2Bi-Armed Activated T Cells) Barbara Ann Karmanos Cancer Instit…·HER2 7 trials |
|---|---|
Overview Program | HER2Bi-Armed Activated T Cells |
Overview Company | Barbara Ann Karmanos Cancer Institute |
Overview Modality | CGT |
Overview Target | HER2 |
Overview Indication | Malignant Ovarian Clear Cell Tumor; Malignant Ovarian Serous Tumor |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer.. A phase II study was conducted to evaluate the safety and efficacy of the combination of HER2 bispecific antibody (HER2Bi)-armed activated T cells (HER2 BAT) and programmed death 1 inhibitor, pembrolizumab. Patients with metastatic castration-res… |
Clinical Safety signal | Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer.. A phase II study was conducted to evaluate the safety and efficacy of the combination of HER2 bispecific antibody (HER2Bi)-armed activated T cells (HER2 BAT) and programmed death 1 inhibitor, pembrolizumab. Patients with metastatic castration-res… |
Clinical Selected reported efficacy | ORR 9% |
Clinical Reported ORR | 9% |
Clinical Result source | ClinicalTrials.gov NCT01022138 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT01022138 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | HER2Bi-Armed Activated T Cells (HER2Bi-Armed Activated T Cells) Barbara Ann Karmanos Cancer Instit…·HER2 7 trials |
|---|---|
Overview Program | HER2Bi-Armed Activated T Cells |
Overview Company | Barbara Ann Karmanos Cancer Institute |
Overview Modality | CGT |
Overview Target | HER2 |
Overview Indication | Malignant Ovarian Clear Cell Tumor; Malignant Ovarian Serous Tumor |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer.. A phase II study was conducted to evaluate the safety and efficacy of the combination of HER2 bispecific antibody (HER2Bi)-armed activated T cells (HER2 BAT) and programmed death 1 inhibitor, pembrolizumab. Patients with metastatic castration-res… |
Clinical Safety signal | Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer.. A phase II study was conducted to evaluate the safety and efficacy of the combination of HER2 bispecific antibody (HER2Bi)-armed activated T cells (HER2 BAT) and programmed death 1 inhibitor, pembrolizumab. Patients with metastatic castration-res… |
Clinical Selected reported efficacy | ORR 9% |
Clinical Reported ORR | 9% |
Clinical Result source | ClinicalTrials.gov NCT01022138 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT01022138 |
추천 비교
추천 비교